Analysis Compares Surgery Partners and Fulgent Genetics Market Standing

A report compares two small-cap healthcare companies, Surgery Partners and Fulgent Genetics, based on various business metrics. The analysis notes that Fulgent Genetics has lower revenue but higher earnings than Surgery Partners. Regarding market sentiment, Surgery Partners has a consensus target price of $19.00, while Fulgent Genetics carries a consensus target price of $27.50.

The comparison covers factors such as price-to-earnings ratios, profitability, and institutional ownership. The report suggests that Surgery Partners is currently trading at a lower price-to-earnings ratio than Fulgent Genetics. The analysis concludes that research analysts view Surgery Partners as the more favorable of the two companies.